GlassScriptPhysician profile
Timothy A Hall
NPI 1114921061
$171,645.87
in general payments reported to CMS, 2019-2025
24 companies · $55K in 2025
The $55K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $18K · 2021: $23K · 2022: $13K · 2023: $23K · 2024: $30K · 2025: $55K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $92K · Travel and Lodging: $7,800 · Food and Beverage: $7,146 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $92,032.00 |
| Travel and Lodging | $7,800.01 |
| Food and Beverage | $7,146.16 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $169,643.93 | 2019-2025 | Da Vinci Surgical System |
| Abbvie INC. | $640.95 | 2019-2022 | |
| Coopersurgical, INC. | $165.24 | 2019-2024 | Paragard T 380a |
| Alydia Health | $151.08 | 2021 | |
| Davol INC. | $149.27 | 2023 | Arista Ah Flexitip |
| Organon LLC | $135.78 | 2022-2025 | Nexplanon |
| Baxter Healthcare | $94.75 | 2025 | Perclot |
| Novo Nordisk INC | $86.37 | 2019-2023 | Wegovy, Saxenda |
| Pfizer INC. | $68.30 | 2023-2025 | |
| Lilly USA, LLC | $62.77 | 2025 | Zepbound |
| Mayne Pharma Commercial LLC | $56.74 | 2021-2024 | |
| Amgen INC. | $53.09 | 2019-2021 | |
| Exeltis, USA INC. | $46.05 | 2022-2023 | Slynd |
| Astellas Pharma US INC | $45.84 | 2024-2025 | Veozah |
| Therapeuticsmd, INC. | $38.84 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $36.34 | 2021 | |
| Hologic Sales and Service, LLC | $36.12 | 2023-2025 | Aptima, Thinprep 2000 Processor, Third Wave |
| Bayer Healthcare Pharmaceuticals INC. | $33.74 | 2020 | |
| Millicent US INC | $21.85 | 2025 | Intrarosa, Femring |
| Sumitomo Pharma America, INC. | $19.24 | 2023 | Myfembree |
| Radius Health, INC. | $15.66 | 2019 | |
| Lupin INC. | $15.34 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.47 | 2019 | |
| Currax Pharmaceuticals LLC | $14.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.